Comparison of cardioprotective efficacy of two thromboxane A2 receptor antagonists

被引:8
|
作者
Ge, ZD
Auchampach, JA
Piper, GM
Gross, GJ
机构
[1] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Div Transplant Surg, Milwaukee, WI 53226 USA
[3] Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA
关键词
hydroxyl radicals; ischemia; KT2-962-TXA(2) receptor antagonist; reperfusion;
D O I
10.1097/00005344-200303000-00018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of the current study was to compare the efficacy of two structurally unrelated thromboxane A(2) (TXA(2)) receptor antagonists, KT2-962 and daltroban (BM 13.505), in a dog model of myocardial ischemia/reperfusion injury. Pentobarbital-anesthetized dogs were subjected to left circumflex coronary artery occlusion for 90 minutes followed by 5 hours of reperfusion. Vehicle, KT2-962(10 mg/kg), or daltroban (10 mg/kg) were administered as intravenous boluses 10 minutes before coronary occlusion. Systemic hemodynamics were measured throughout the experiments and regional myocardial blood flow was measured by the radioactive microsphere technique. At the end of the reperfusion period; myocardial infarct size was quantified by staining with triphenyltetrazolium chloride. Neither KT2-962 nor daltroban significantly altered heart rate, mean arterial blood pressure, or regional myocardial blood flow. The content of myeloperoxidase activity in the ischemic/reperfused tissue, an index of neutrophil infiltration, was not significantly different among the three treatment groups. However, administration of KT2-962, but not daltroban, significantly reduced the incidence of ventricular fibrillation during the ischemic period and significantly reduced myocardial infarct size expressed as a percentage of the risk region (approximately 40%). Subsequent in-vitro assays using electron spin resonance spectroscopy demonstrated that KT2-962 inhibited the formation of hydroxyl radicals, whereas daltroban had no effect. These results suggest that the beneficial effects of KT2-962 may be due to its direct free radical scavenging properties rather than its ability to block TXA(2) receptors.
引用
收藏
页码:481 / 488
页数:8
相关论文
共 50 条
  • [31] SYNTHETIC THROMBOXANE-A2 AND CHARACTERIZATION OF THE THROMBOXANE RECEPTOR USING A NOVEL CLASS OF RECEPTOR ANTAGONISTS
    MORTON, HE
    EVANS, J
    LEVEILLE, C
    LORD, A
    GILLARD, JW
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1988, 195 : 122 - MEDI
  • [32] The β1-Subunit of the MaxiK Channel Associates with the Thromboxane A2 Receptor and Reduces Thromboxane A2 Functional Effects
    Li, Min
    Zhang, Zhu
    Koh, Huilin
    Lu, Rong
    Jiang, Zhaorong
    Alioua, Abderrahmane
    Garcia-Valdes, Jesus
    Stefani, Enrico
    Toro, Ligia
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (05) : 3668 - 3677
  • [33] Protection of atherogenesis in thromboxane A2 receptor-deficient mice is not associated with thromboxane A2 receptor in bone marrow-derived cells
    Zhuge, Xin
    Arai, Hidenori
    Xu, Yang
    Murayama, Toshinorl
    Kobayashi, Takuya
    Narumiya, Shuh
    Kita, Toru
    Yokode, Masayuki
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 351 (04) : 865 - 871
  • [34] Synthesis and pharmacological evaluation of 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as novel thromboxane A2 receptor antagonists
    Bambi-Nyanguile, Sylvie-Mireille
    Hanson, Julien
    Ooms, Annie
    Alpan, Lutfiye
    Kolh, Philippe
    Dogne, Jean-Michel
    Pirotte, Bernard
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 65 : 32 - 40
  • [35] MEDI 267-Development of dual-acting benzofurans and benzomorpholines as thromboxane A2 receptor antagonists and prostacyclin receptor agonists
    Ohno, Michihiro
    Miyamoto, Mitsuko
    Takeda, Takahiro
    Tanaka, Yoichiro
    Makita, Kei
    Hoshi, Kazuhiro
    Yamada, Naohiro
    Ohtake, Atsushi
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
  • [36] Synthesis and biological activity of 4-methyl-3,5-dioxane derivatives as thromboxane A2 receptor antagonists
    Marusawa, H
    Setoi, H
    Kuroda, A
    Sawada, A
    Seki, J
    Motoyama, Y
    Tanaka, H
    BIOORGANIC & MEDICINAL CHEMISTRY, 1999, 7 (11) : 2635 - 2645
  • [37] Novel regulatory mechanisms of thromboxane A2 receptor function
    Nakahata, Norimichi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 109 : 38P - 38P
  • [38] Directed vascular expression of the thromboxane A2 receptor.
    Rocca, B
    Loeb, AL
    Eng, V
    Vezza, R
    Habib, A
    Funk, CD
    FitzGerald, GA
    JOURNAL OF INVESTIGATIVE MEDICINE, 1998, 46 (03) : 230A - 230A
  • [39] SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF NOVEL AMINO-PROSTANOIDS - POTENT AND ORALLY EFFECTIVE THROMBOXANE A2 RECEPTOR ANTAGONISTS
    CAMPBELL, IB
    COLLINGTON, EW
    FINCH, H
    HALLETT, P
    HAYES, R
    LUMLEY, P
    MILLS, K
    WALLIS, CJ
    WHITE, BP
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1991, 1 (12) : 689 - 694
  • [40] The 5′ region of the human thromboxane A2 receptor gene
    Saffak, T
    Nüsing, RM
    PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2002, 67 (01): : 25 - 31